RECQL (also known as RECQ1 or RECQL1) is a member of the RecQ helicase family, which plays critical roles in maintaining genomic stability by unwinding DNA structures during replication, repair, and recombination. Unlike other RecQ helicases (e.g., BLM, WRN), RECQL is ubiquitously expressed and involved in multiple DNA repair pathways, including homologous recombination repair, base excision repair, and replication stress response. It resolves stalled replication forks, prevents excessive DNA strand resection, and suppresses illegitimate recombination, making it essential for genome integrity. Dysregulation of RECQL has been linked to cancer susceptibility and poor prognosis, though its direct association with a specific hereditary disorder (unlike BLM or WRN mutations) remains unclear.
RECQL antibodies are essential tools for studying its expression, localization, and function in cellular contexts. These antibodies are typically developed against specific epitopes of the human RECQL protein and validated for applications such as Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation. Researchers use them to investigate RECQL’s role in DNA damage response, its interaction with repair proteins (e.g., PARP1. RAD51), and its potential as a biomarker in cancers like breast, ovarian, or pancreatic adenocarcinoma. Commercial RECQL antibodies are often raised in rabbits or mice, with validation across cell lines and tissue samples. Specificity and cross-reactivity checks are crucial due to structural similarities among RecQ helicases. Recent studies also explore RECQL as a therapeutic target, driving demand for high-quality antibodies in preclinical research.